News

January 30, 2019

Innovent Seeks Chinese Regulatory Approval for Proposed Biosimilar Bevacizumab

Innovent Biologics, a China-based biopharmaceutical company, recently submitted a New Drug Application for its proposed bevacizumab biosimilar, IBI-305, referencing Avastin, to the Chinese regulatory agency, the National Medical Products Administration (NMPA).

The application is seeking regulatory approval for the treatment of non–small cell lung cancer (NSCLC), colorectal cancer, and other malignant tumors. The application submitted to the NMPA was based on clinical data from 2 studies: a phase 3 study that compared the efficacy and safety of the biosimilar with the reference product in advanced non-squamous NSCLC, and a trial that investigated the pharmacokinetics of both drugs in healthy subjects.

“Two clinical studies have been conducted with bevacizumab injection as the control drug. based on the high-quality clinical data, the NDA application of IBI-305 has been accepted by the NMPA. We believe that the high quality bevacizumab biosimilar will improve drug availability and benefit more patients and their families,” said Li Zhang, professor at the cancer hospital of Sun Yat-Sen University in a statement.

Read more

Back to News